Tabor Asset Management LP Acquires Shares of 8,595 Amedisys, Inc. (NASDAQ:AMED)

Tabor Asset Management LP acquired a new stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 8,595 shares of the health services provider's stock, valued at approximately $796,000.

A number of other institutional investors have also added to or reduced their stakes in AMED. Raymond James Financial Inc. acquired a new stake in Amedisys during the fourth quarter worth approximately $215,000. Swiss National Bank grew its position in Amedisys by 0.9% in the 4th quarter. Swiss National Bank now owns 64,400 shares of the health services provider's stock valued at $5,847,000 after purchasing an additional 600 shares during the period. Xponance Inc. increased its stake in Amedisys by 3.5% during the 4th quarter. Xponance Inc. now owns 4,349 shares of the health services provider's stock valued at $395,000 after purchasing an additional 148 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Amedisys during the fourth quarter worth $590,000. Finally, Vanguard Group Inc. lifted its stake in shares of Amedisys by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 3,216,120 shares of the health services provider's stock valued at $291,992,000 after buying an additional 10,817 shares in the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Royal Bank Of Canada reiterated an "outperform" rating and issued a $100.00 target price on shares of Amedisys in a research note on Wednesday, April 16th. Wall Street Zen cut Amedisys from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 24th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $100.75.

Amedisys Stock Up 0.3%

Amedisys stock traded up $0.25 on Monday, hitting $97.71. 179,634 shares of the stock traded hands, compared to its average volume of 412,686. The business's fifty day simple moving average is $96.01 and its 200 day simple moving average is $93.77. The firm has a market cap of $3.21 billion, a P/E ratio of 36.06, a price-to-earnings-growth ratio of 1.32 and a beta of 0.94. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.27. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, beating analysts' consensus estimates of $1.13 by $0.12. The company had revenue of $594.78 million during the quarter, compared to analyst estimates of $597.43 million. Amedisys had a return on equity of 12.52% and a net margin of 3.79%. The firm's revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the company earned $1.03 EPS. As a group, sell-side analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.